AcquisitionsJun 26, 2026, 04:13 PM
BriaCell Subsidiary Acquires sCD80 License; Reports Q3 Loss
AI Summary
BriaCell Therapeutics Corp.'s subsidiary, BriaPro Therapeutics Corp., filed its unaudited interim consolidated financial statements for the three and nine months ended April 30, 2026. A key development was BriaPro's acquisition of an exclusive license for Soluble CD80 (sCD80) for cancer treatment from BriaCell, valued at $846,532, paid in shares. BriaPro reported a net loss of $712,236 for the nine-month period and received a $300,000 advance from a $3,000,000 credit facility from BriaCell to fund sCD80 research and development.
Key Highlights
- BriaPro acquired exclusive sCD80 license from BriaCell for $846,532 in shares.
- BriaCell's ownership in BriaPro increased to approximately 78% post-acquisition.
- BriaPro reported a net loss of $712,236 for the nine months ended April 30, 2026.
- Research and development expenses rose to $649,991 for the nine-month period.
- BriaPro received $300,000 from BriaCell's $3,000,000 credit facility.
- Cash and cash equivalents for BriaPro reached $299,950 as of April 30, 2026.
- BriaPro's intangible assets increased to $1,019,603, including sCD80.
- Jamieson Bondarenko appointed Chairman of BriaPro's board.
Price Impact
More from BCTX